Literature DB >> 27220431

Two Novel Heparin-binding Vascular Endothelial Growth Factor Splices, L-VEGF144 and L-VEGF138, are Expressed in Human Glioblastoma Cells.

Chiung-Chyi Shen1, Wen-Yu Cheng, Ming-Tsang Chiao, Yea-Jiuan Liang, Tsuo-Fei Mao, Bai-Shuan Liu.   

Abstract

The expression levels of different vascular endothelial growth factor A (VEGF) isoforms are associated with the angiogenesis and the patient's prognoses in human cancers. Ribosomes specifically scan from 5' to 3' CUG initiation codon in the long 5'-untranslated region (5'-UTR) of the VEGF mRNA, resulting in the generation of high mol wt VEGF isoform [call large VEGF (L-VEGF)]. Alternative splicing of VEGF mRNA transcripts results in several isoforms with distinct properties that are dependent up their exon compositions. In this study, we observed two novel kinds of splicing VEGF isoforms that transcripted at the first upstream CUG codon, and which we have named large-VEGF144 (LVEGF144), and large-VEGF138 (L-VEGF138). The expression levels of messenger RNA for the different VEGF splice forms were analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR). After DNA sequencing, the genetic structure of L-VEGF144 involved not only a partial exon 1, exon 6a, and exons 7-8, but also an unique 108- nucleotides insertion of VEGF intron 5 interposed between exon 1 and exon 6. At the same time, L-VEGF144 lacked most of the Nterminal fragments (exons 1-5). We further found that a specific detection model could easily and rapidly confirm the presence of L-VEGF144 mRNA fragments in the biopsies or cell lines via RT-PCR assay. In addition, we used visible fluorescent fusion proteins to prove that both L-VEGF144 and L-VEGF138 have nuclear localization ability. Taken together, the findings of this study indicate that, unlike previously identified isoforms, these novel VEGF isoforms are likely to suggest a further level of complexity in the angiogenic process.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27220431     DOI: 10.2174/1567202613666160525115446

Source DB:  PubMed          Journal:  Curr Neurovasc Res        ISSN: 1567-2026            Impact factor:   1.990


  5 in total

1.  High expression of a novel splicing variant of VEGF, L-VEGF144 in glioblastoma multiforme is associated with a poorer prognosis in bevacizumab treatment.

Authors:  Wen-Yu Cheng; Chiung-Chyi Shen; Ming-Tsang Chiao; Yea-Jiuan Liang; Tsuo-Fei Mao; Bai-Shuan Liu; Jun-Peng Chen
Journal:  J Neurooncol       Date:  2018-06-16       Impact factor: 4.130

2.  Both p53 codon 72 Arg/Arg and pro/Arg genotypes in glioblastoma multiforme are associated with a better prognosis in bevacizumab treatment.

Authors:  Chiung-Chyi Shen; Wen-Yu Cheng; Chung-Hsin Lee; Xue-Jun Dai; Ming-Tsang Chiao; Yea-Jiuen Liang; Wan-Yu Hsieh; Tsuo-Fei Mao; Guo-Shi Lin; Shou-Ren Chen; Bai-Shuan Liu; Jun-Peng Chen
Journal:  BMC Cancer       Date:  2020-07-29       Impact factor: 4.430

3.  Overexpression of HOXC10 promotes angiogenesis in human glioma via interaction with PRMT5 and upregulation of VEGFA expression.

Authors:  Zhanyao Tan; Kun Chen; Wenjiao Wu; Yanqing Zhou; Jinrong Zhu; Geyan Wu; Lixue Cao; Xin Zhang; Hongyu Guan; Yi Yang; Wei Zhang; Jun Li
Journal:  Theranostics       Date:  2018-10-06       Impact factor: 11.556

Review 4.  Pathogenic diversity of RNA variants and RNA variation-associated factors in cancer development.

Authors:  Hee Doo Yang; Suk Woo Nam
Journal:  Exp Mol Med       Date:  2020-04-28       Impact factor: 8.718

Review 5.  Splicing Dysregulation as Oncogenic Driver and Passenger Factor in Brain Tumors.

Authors:  Pamela Bielli; Vittoria Pagliarini; Marco Pieraccioli; Cinzia Caggiano; Claudio Sette
Journal:  Cells       Date:  2019-12-18       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.